Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J4GO
|
|||
| Former ID |
DAP000601
|
|||
| Drug Name |
Dichlorphenamide
|
|||
| Synonyms |
dichlorphenamide; Diclofenamide; 120-97-8; 4,5-dichlorobenzene-1,3-disulfonamide; Dichlofenamide; Dichlorophenamide; Daranide; Dichlorphenamid; Glauconide; Antidrasi; Glaucol; Oratrol; Diclofenamidum; Diclofenamida; Diclofenamid; Barastonin; Glaumid; Glafco; Glajust; 4,5-Dichloro-m-benzenedisulfonamide; 1,3-Benzenedisulfonamide, 4,5-dichloro-; Diclofenamidum [INN-Latin]; 4,5-Dichloro-1,3-disulfamoylbenzene; 1,3-Disulfamoyl-4,5-dichlorobenzene; Diclofenamida [INN-Spanish]; 1,3-Disulfamyl-4,5-dichlorobenzene; Dasanide; Keveyis; Antidrasi; Dichlorphenamide [BAN]; Llorens Brand of Dichlorphenamide; Merck Brand of Dichlorphenamide; CB 8000; I7A; Daranide (TN); Dichlorophenamide (DCP); Dichlorphenamide (USP); Diclofenamide (JP15/INN); 3,4-Dichloro-5-sulfamylbenzenesulfonamide; 4,5-Dichloro-1,3-benzenedisulfonamide; 4,5-Dichloro-benzene-1,3-disulfonic acid diamide; 4,5-DICHLOROBENZENE-1,3-DISULFONAMIDE
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic glaucoma [ICD-11: 9C61.0Z; ICD-9: 365] | Approved | [1], [2] | |
| Therapeutic Class |
Antiglaucomic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H6Cl2N2O4S2
|
|||
| Canonical SMILES |
C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
|
|||
| InChI |
1S/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)
|
|||
| InChIKey |
GJQPMPFPNINLKP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 120-97-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9662, 5394315, 7847584, 8151933, 10321980, 10505613, 11112264, 11466837, 11467957, 11486334, 14898599, 26717464, 29222184, 46505039, 46511453, 47291265, 47662454, 47662455, 48185135, 48415882, 49698651, 49879995, 50100403, 50920273, 53812947, 56463645, 57321571, 61013445, 85787355, 87350459, 92125643, 92729678, 99375170, 99444419, 103164700, 103914449, 104253501, 104302345, 118050517, 118307481, 121363314, 124757623, 124801457, 125164427, 125659078, 126652477, 126687904, 126729448, 127963474, 134337892
|
|||
| ChEBI ID |
CHEBI:101085
|
|||
| ADReCS Drug ID | BADD_D00652 ; BADD_D02437 | |||
| SuperDrug ATC ID |
S01EC02
|
|||
| SuperDrug CAS ID |
cas=000120978
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase I (CA-I) | Target Info | Modulator | [3] |
| Carbonic anhydrase II (CA-II) | Target Info | Inhibitor | [4] | |
| KEGG Pathway | Nitrogen metabolism | |||
| Proximal tubule bicarbonate reclamation | ||||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| EGFR1 Signaling Pathway | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Pathway Interaction Database | C-MYB transcription factor network | |||
| Reactome | Erythrocytes take up carbon dioxide and release oxygen | |||
| Erythrocytes take up oxygen and release carbon dioxide | ||||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Reversible Hydration of Carbon Dioxide | |||
| Uptake of Carbon Dioxide and Release of Oxygen by Erythrocytes | ||||
| Uptake of Oxygen and Release of Carbon Dioxide by Erythrocytes | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6807). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 011366. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 4 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.